ViiV Healthcare BV — China drug registrations and re-registration deadlines
7 certificates in the NMPA overseas-manufactured drug database (境外生产药品库), snapshot 2026-06-28. Earliest re-registration deadline: 2027-04-17.
| Approval number | Product | Certificate expires | Re-registration deadline (Art. 82) |
|---|---|---|---|
| 国药准字HJ20220081 | Dolutegravir Sodium and Rilpivirine Hydrochloride Tablets 多替拉韦利匹韦林片 | 2027-10-17 | 2027-04-17 |
| 国药准字HJ20230060 | Dolutegravir Sodium Dispersible Tablets 多替拉韦钠分散片 | 2028-05-28 | 2027-11-28 |
| 国药准字HJ20230092 | VOCABRIA 卡替拉韦注射液 | 2028-07-10 | 2028-01-10 |
| 国药准字HJ20230093 | VOCABRIA 卡替拉韦注射液 | 2028-07-10 | 2028-01-10 |
| 国药准字HJ20230094 | VOCABRIA 卡替拉韦钠片 | 2028-07-10 | 2028-01-10 |
| 国药准字HJ20210013 | Lamivudine and Dolutegravir Sodium Tablets 拉米夫定多替拉韦片 | 2030-11-25 | 2030-05-25 |
| 国药准字HJ20150202 | ZIAGEN 硫酸阿巴卡韦口服溶液 | 2031-04-02 | 2030-10-02 |
Under the Provisions for Drug Registration (药品注册管理办法) Art. 82, an application to renew an overseas-manufactured drug registration is filed with the Center for Drug Evaluation no later than 6 months before the certificate expires; the filing line column is that arithmetic applied to the expiry cell. Art. 84(1): a certificate with no application by expiry is not re-registered and is cancelled at expiry. Every figure is taken from the public NMPA database as of 2026-06-28, or computed from it. Registration data changes; the NMPA portal governs. This page states no view on whether any of these products' Domestic Responsible Person (境内责任人) arrangements meet NMPA Announcement No. 137 — that cannot be determined from a public entry.